The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
Open accessAbstract
Overview.Clinical types of MS.MS is a chronic recurrent inflammatory disorder of the CNS.The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser extent, the axons and nerve cells themselves.[1][2][3][4][5] The symptoms of MS vary, depending in part on the location of plaques within the CNS.Common symptoms include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia.5 Four different clinical courses of MS have been defined.6 The first, relapsing-remitting MS (RRMS), is characterized by self-limited attacks of neurologic dysfunction.These attacks develop acutely, evolving over days to weeks.Over the next several weeks to months, most patients experience a recovery of function that is often (but not always) complete.Between attacks the patient is neurologically and symptomatically stable.The second clinical course, secondary progressive MS (SPMS), begins as RRMS, but at some point the attack rate is reduced and the course becomes characterized by a steady deterioration in function unrelated to acute attacks.The third clinical type, primary progressive MS (PPMS), is characterized by a steady decline in function from the beginning without acute attacks.The fourth type, progressive-relapsing MS (PRMS), also begins with a progressive course although these patients also experience occasional attacks.Outcome measures in MS clinical trials.Evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy.Clearly, the most important therapeutic aim of any disease-modifying treatment of MS is to prevent or postpone long-term disability.However, long-term disability in MS often evolves slowly over many years.[1][2][3] Clinical trials, by contrast, study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy.As a result, it is important to validate any short-term measure by its correlation with the actual patient outcome many years later.For a discussion of these issues, interested readers should consult the full-length assessment on the Neurology Web site at www.neurology.org.Scope of this guideline.The purpose of this assessment is to consider the clinical utility of these disease-modifying agents including the anti-inflammatory, immunomodulatory, and immunosuppressive treatments that are currently available.Symptomatic and reparative therapies will not be considered. Before considering the evidence from individualAdditional material related to this article can be found on the Neurology Web site.Go to www.neurology.org and scroll down the Table of Contents for the January 22 issue to find the title link for this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationMcDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Cognitive dysfunction in multiple sclerosis.: I. Frequency, patterns, and prediction
Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.685 · Cited by 2,110
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Beck, R. W., Cleary, P. A., Anderson, M. M., Keltner, J. L., Shults, W. T., Kaufman, D. I., Buckley, E. G., Corbett, J. J., Kupersmith, M. J., Miller, N. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260901 · Cited by 1,355
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. R. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,190
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Procedures for Comparing Samples with Multiple Endpoints
O'Brien, P. C. (1984) · Biometrics · doi:10.2307/2531158 · Cited by 1,162
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning
Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.692 · Cited by 890
Hauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., & Weiner, H. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301273080401 · Cited by 827
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Beck, R. W., Cleary, P. A., Trobe, J. D., Kaufman, D. I., Kupersmith, M. J., Paty, D. W., & Brown, C. H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292403 · Cited by 579
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Kappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O'Riordan, J. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 484
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Li, D. K. B., Paty, D. W., & UBC MS/MRI Analysis Research Group and the PRISMS Study Group (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-p · Cited by 380
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J., Lublin, F., Miller, A., Petkau, J., Rao, S., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420318 · Cited by 371
Milligan, N. M., Newcombe, R., & Compston, D. A. (1987) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.50.5.511 · Cited by 364
Influence of the Carbohydrate Moiety on the Stability of Glycoproteins
Wang, C., Eufemi, M., Turano, C., & Giartosio, A. (1996) · Biochemistry · doi:10.1021/bi9517704 · Cited by 344
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., et al. (1998) · Neurology · doi:10.1212/wnl.50.5.1266 · Cited by 333
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Noseworthy, J. H., Vandervoort, M. K., Wong, C. J., & Ebers, G. C. (1990) · Neurology · doi:10.1212/wnl.40.6.971 · Cited by 328
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974512425 · Cited by 304
Goodkin, D. E., Rudick, R. A., Medendorp, S. V., Daughtry, M. M., Schwetz, K. M., Fischer, J., & van Dyke, C. (1995) · Annals of Neurology · doi:10.1002/ana.410370108 · Cited by 304
Optic neuritis: A population‐based study in Olrnsted County, Minnesota
Rodriguez, M., Siva, A., Cross, S. A., O'Brien, P. C., & Kurland, L. T. (1995) · Neurology · doi:10.1212/wnl.45.2.244 · Cited by 290
Cladribine in treatment of chronic progressive multiple sclerosis
SIPE, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91046-4 · Cited by 283
Millefiorini, E., Gasperini, C., Pozzilli, C., D'Andrea, F., Bozzao, A., Calo', A., Bernini, M. L., Gambi, D., Prencipe, M., Bastianello, S., et al. (1997) · Journal of Neurology · doi:10.1007/s004150050066 · Cited by 269
Hawkins, S. A., & McDonnell, G. V. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.2.148 · Cited by 260
Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo—final report
(1970) · Neurology · doi:10.1212/wnl.20.5_part_2.1 · Cited by 259
Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses
Achiron, A., Gabbay, U., Gilad, R., Hassin-Baer, S., Barak, Y., Gornish, M., Elizur, A., Goldhammer, Y., & Sarova-Pinhas, I. (1998) · Neurology · doi:10.1212/wnl.50.2.398 · Cited by 256
A neurologic rating scale (NRS) for use in multiple sclerosis
Sipe, J. C., Knobler, R. L., Braheny, S. L., Rice, G. P. A., Panitch, H. S., & Oldstone, M. B. A. (1984) · Neurology · doi:10.1212/wnl.34.10.1368 · Cited by 255
Mechanisms of action of glatiramer acetate in multiple sclerosis
Neuhaus, O., Farina, C., Wekerle, H., & Hohlfeld, R. (2001) · Neurology · doi:10.1212/wnl.56.6.702 · Cited by 248
Weiner, H. L., Mackin, G. A., Orav, E. J., Hafler, D. A., Dawson, D. M., LaPierre, Y., Herndon, R., Lehrich, J. R., Hauser, S. L., Turel, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.5.910 · Cited by 248
Johnson, K. P., Brooks, B. R., Ford, C. C., Goodman, A., Guarnaccia, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Pruitt, A., Rose, J. W., et al. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600407 · Cited by 247
Ross, C., Clemmesen, K. M., Svenson, M., S�rensen, P. S., Koch‐Henriksen, N., Skovgaard, G. L., Bendtzen, K., & the Danish Multiple Sclerosis Study Group (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v · Cited by 243
Smith, M. E., Stone, L. A., Albert, P. S., Frank, J. A., Martin, R., Armstrong, M., Maloni, H., McFarlin, D. E., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410330511 · Cited by 241
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
Rudick, R. A., Goodkin, D. E., Jacobs, L. D., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Granger, C. V., Simon, J. H., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.358 · Cited by 232
The Epidemiology of Multiple Sclerosis
Hogancamp, W. E., Rodriguez, M., & Weinshenker, B. G. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.9.871 · Cited by 225
Overview of azathioprine treatment in multiple sclerosis
Yudkin, P. L., Ellison, G. W., Ghezzi, A., Goodkin, D. E., Hughes, R. A. C., McPherson, K., Mertin, J., & Milanese, C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91909-e · Cited by 219
Ebers, G. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530240016003 · Cited by 216
Optic Neuritis Treatment Trial
Levi, L. (1995) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199512000-00045 · Cited by 210
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., & Zyroff, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1716 · Cited by 208
Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P., & Aimard, G. (1996) · Neurology · doi:10.1212/wnl.46.6.1607 · Cited by 203
THE PROBLEM OF MULTIPLE INFERENCE IN STUDIES DESIGNED TO GENERATE HYPOTHESES
THOMAS, D. C., SIEMIATYCKI, J., DEWAR, R., ROBINS, J., GOLDBERG, M., & ARMSTRONG, B. G. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114189 · Cited by 190
Miller, D. H., Thompson, A. J., Morrissey, S. P., MacManus, D. G., Moore, S. G., Kendall, B. E., Moseley, I. F., & McDonald, W. I. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.6.450 · Cited by 188
Durelli, L., Cocito, D., Riccio, A., Barile, C., Bergamasco, B., Baggio, G. F., Perla, F., Delsedime, M., Gusmaroli, G., & Bergamini, L. (1986) · Neurology · doi:10.1212/wnl.36.2.238 · Cited by 184
Total brain N -acetylaspartate: A new measure of disease load in MS
Gonen, O., Catalaa, I., Babb, J. S., Ge, Y., Mannon, L. J., Kolson, D. L., & Grossman, R. I. (2000) · Neurology · doi:10.1212/wnl.54.1.15 · Cited by 181
Weiner, H. L., Dau, P. C., Khatri, B. O., Petajan, J. H., Birnbaum, G., McQuillen, M. P., Fosburg, M. T., Feldstein, M., & Orav, E. J. (1989) · Neurology · doi:10.1212/wnl.39.9.1143 · Cited by 180
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Drexler, E., Keilson, M., Spada, V., Weiss, W., Appel, S., Rolak, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.533 · Cited by 173
Gronseth, G., & Ashman, E. J. (2000) · Neurology · doi:10.1212/wnl.54.9.1720 · Cited by 166
Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers
SALMON, P., LE COTONNEC, J.-Y., GALAZKA, A., ABDUL-AHAD, A., & DARRAGH, A. (1996) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1996.16.759 · Cited by 165
Barkhof, F., Scheltens, P., Frequin, S. T., Nauta, J. J., Tas, M. W., Valk, J., & Hommes, O. R. (1992) · American Journal of Roentgenology · doi:10.2214/ajr.159.5.1414773 · Cited by 165
Amato, M. P., Fratiglioni, L., Groppi, C., Siracusa, G., & Amaducci, L. A. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310052017 · Cited by 162
Barkhof, F., Hommes, O. R., Scheltens, P., & Valk, J. (1991) · Neurology · doi:10.1212/wnl.41.8.1219 · Cited by 148
A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis
Sellebjerg, F. T., Nielsen, H., Frederiksen, J. L., & Olesen, J. (1999) · Neurology · doi:10.1212/wnl.52.7.1479 · Cited by 147
Rothman, K. J. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-3-445 · Cited by 145
Romine, J. S., Sipe, J. C., Koziol, J. A., Zyroff, J., & Beutler, E. (1999) · Proceedings of the Association of American Physicians · doi:10.1046/j.1525-1381.1999.09115.x · Cited by 142
Amato, M. P., Ponziani, G., Bartolozzi, M. L., & Siracusa, G. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00143-4 · Cited by 138
Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
Thompson, A. J., Kennard, C., Swash, M., Summers, B., Yuill, G. M., Shepherd, D. I., Roche, S., Perkin, G. D., Loizou, L. A., Ferner, R., et al. (1989) · Neurology · doi:10.1212/wnl.39.7.969 · Cited by 130
Molecular pathogenesis of multiple sclerosis
Bar‐Or, A., de Oliveira, E. M. L., Anderson, D. E., & Hafler, D. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00193-9 · Cited by 121
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
Teitelbaum, D., Milo, R., Arnon, R., & Sela, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.137 · Cited by 112
Wolinsky, J. S., Narayana, P. A., & Johnson, K. P. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700107 · Cited by 109
The effect of high‐dose steroids on MRI gadolinium enhancement in acute demyelinating lesions
Burnham, J. A., Wright, R. R., Dreisbach, J. N., & Murray, R. S. (1991) · Neurology · doi:10.1212/wnl.41.9.1349 · Cited by 99
The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis
Noseworthy, J. H., O’Brien, P. C., Erickson, B. J., Lee, D. D., Sneve, D., Ebers, G. C., Rice, G. P. A., Auty, A., Hader, W. J., Kirk, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.5.1342 · Cited by 97
The Immunobiology of Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System
Conlon, P. J., Oksenberg, J. R., Zhang, J., & Steinman, L. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0239 · Cited by 95
Sharief, M. K., & Thompson, E. J. (1991) · Annals of Neurology · doi:10.1002/ana.410290206 · Cited by 87
Liu, C., & Blumhardt, L. D. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.450 · Cited by 86
A comparative study of the relative bioavailability of different interferon beta preparations
Deisenhammer, F., Mayringer, I., Harvey, J. L., Dilitz, E., Gasse, T., Stadlbauer, D., Reindl, M., & Berger, T. (2000) · Neurology · doi:10.1212/wnl.54.11.2055 · Cited by 84
New treatments and azathioprine in multiple sclerosis
Palace, J. A., & Rothwell, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)24030-4 · Cited by 74
Interferon immunogenicity: technical evaluation of interferon-alpha 2a.
Hochuli, E. (1997) · PubMed · Cited by 71
Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration
Khan, O., Xia, Q., Bever, C. T., Johnson, K. P., PANITCH, H. S., & Dhib-Jalbut, S. S. (1996) · Neurology · doi:10.1212/wnl.46.6.1639 · Cited by 64
Goodin, D. S. (1999) · Neuroepidemiology · doi:10.1159/000069408 · Cited by 59
Alam, J. J., Goelz, S. E., Rioux, P. P., Scaramucci, J., Jones, W. E., McAllister, A., Campion, M., & Rogge, M. C. (1997) · Pharmaceutical Research · doi:10.1023/a:1012128406432 · Cited by 57
Are Appropriateness Criteria Ready for Use in Clinical Practice?
Shekelle, P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440912 · Cited by 55
A questionnaire to assess neurological impairment in multiple sclerosis
Goodin, D. S. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400508 · Cited by 52
Goldblatt, D. (2001) · Neurology · doi:10.1212/wnl.56.2.148 · Cited by 51
Milanese, C., Mantia, L. L., Salmaggi, A., Campi, A., Eoli, M., Scaioli, V., Nespolo, A., & Corridori, F. (2008) · European Neurology · doi:10.1159/000116368 · Cited by 45
A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis
Reder, A. T., Thapar, M., & Jensen, M. A. (1994) · Neurology · doi:10.1212/wnl.44.12.2289 · Cited by 44
Invited Commentary: p Values, Hypothesis Tests, and Likelihood
Bellhouse, D. R. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116701 · Cited by 13
Cited by
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Metadata
- Venue
- Neurology
- Published
- 2002-01-22
- Volume
- 58
- Issue
- 2
- Pages
- 169-178
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2034432056
- Cited by
- 797
- References
- 105
- FWCI
- 36.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.